An observational study in Sarcoma, Soft Tissue, sponsored by Eisai Co., Ltd.. Completed at 2 sites in Japan. Per ClinicalTrials.gov, last updated 2020-04-06.
Sponsored by Eisai Co., Ltd. · Observational
The purpose of this study is to understand safety and efficacy in participants with soft tissue sarcomas.
1,667 studies on the registry are indexed under Sarcoma; 393 are open to participants now.
This study's enrollment of 256 is above the median of 121 across 238 observational studies indexed under Sarcoma.
Browse Sarcoma studies →Eisai Co., Ltd. is the lead sponsor of 149 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants with soft tissue sarcoma who will receive eribulin mesylate per the approved indication in routine clinical practice.
Exclusion Criteria:
Drug: Eribulin mesylate
Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
Also known as: Halaven Injection, E7389
Number of Adverse Events (AEs) and Adverse Drug Reactions (ADRs)
Time frame: up to 2 years
Survival Rate at Year 2
Time frame: up to 2 years
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eisai Co., Ltd.